How case-aware filtering improves clinical-trial shortlisting
Shortlist quality depends less on registry volume and more on how accurately listings are mapped to case context.
When biomarker profile, stage, performance status, and prior treatment line are evaluated together, prioritization becomes more meaningful.
This makes the difference between “many records” and “the right records” operationally visible.
The system does not make clinical decisions; it helps teams use pre-decision review time more efficiently.